TrialThoracic cancer2021

Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.

Zhi-Qin Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.